Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

Angela L. Bosma; Linde E. M. de Wijs; Michel H. Hof; Beau R. van Nieuwenhuizen; Louise A. A. Gerbens; Maritza A. Middelkamp-Hup; DirkJan Hijnen; Phyllis I. Spuls

doi:https://doi.org/10.1016/j.jaad.2021.02.072

Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

Angela L. Bosma, Linde E. M. de Wijs, Michel H. Hof, Beau R. van Nieuwenhuizen, Louise A. A. Gerbens, Maritza A. Middelkamp-Hup, DirkJan Hijnen, Phyllis I. Spuls

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	e173-e174
Journal	Journal of the American Academy of Dermatology
Volume	85
Issue number	3
Early online date	2021
DOIs	https://doi.org/10.1016/j.jaad.2021.02.072
Publication status	Published - Sept 2021

Access to Document

https://doi.org/10.1016/j.jaad.2021.02.072

Cite this

Bosma, A. L., de Wijs, L. E. M., Hof, M. H., van Nieuwenhuizen, B. R., Gerbens, L. A. A., Middelkamp-Hup, M. A., Hijnen, D., & Spuls, P. I. (2021). Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”. Journal of the American Academy of Dermatology, 85(3), e173-e174. https://doi.org/10.1016/j.jaad.2021.02.072

Bosma, Angela L. ; de Wijs, Linde E. M. ; Hof, Michel H. et al. / Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”. In: Journal of the American Academy of Dermatology. 2021 ; Vol. 85, No. 3. pp. e173-e174.

@article{01b472a23345435a967a7238b499cc06,

title = "Response to: “Comment on {\textquoteleft}Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry{\textquoteright}”",

author = "Bosma, {Angela L.} and {de Wijs}, {Linde E. M.} and Hof, {Michel H.} and {van Nieuwenhuizen}, {Beau R.} and Gerbens, {Louise A. A.} and Middelkamp-Hup, {Maritza A.} and DirkJan Hijnen and Spuls, {Phyllis I.}",

note = "Funding Information: Funding sources: The original study was partly funded by a governmental grant through ZonMw (The Netherlands Organization for Health Research and Development), program Rational Pharmacotherapy.",

year = "2021",

month = sep,

doi = "https://doi.org/10.1016/j.jaad.2021.02.072",

language = "English",

volume = "85",

pages = "e173--e174",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "3",

}

Bosma, AL, de Wijs, LEM, Hof, MH, van Nieuwenhuizen, BR, Gerbens, LAA , Middelkamp-Hup, MA, Hijnen, D & Spuls, PI 2021, 'Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”', Journal of the American Academy of Dermatology, vol. 85, no. 3, pp. e173-e174. https://doi.org/10.1016/j.jaad.2021.02.072

Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”. / Bosma, Angela L.; de Wijs, Linde E. M.; Hof, Michel H. et al.
In: Journal of the American Academy of Dermatology, Vol. 85, No. 3, 09.2021, p. e173-e174.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

AU - Bosma, Angela L.

AU - de Wijs, Linde E. M.

AU - Hof, Michel H.

AU - van Nieuwenhuizen, Beau R.

AU - Gerbens, Louise A. A.

AU - Middelkamp-Hup, Maritza A.

AU - Hijnen, DirkJan

AU - Spuls, Phyllis I.

N1 - Funding Information: Funding sources: The original study was partly funded by a governmental grant through ZonMw (The Netherlands Organization for Health Research and Development), program Rational Pharmacotherapy.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85103981196&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jaad.2021.02.072

DO - https://doi.org/10.1016/j.jaad.2021.02.072

M3 - Comment/Letter to the editor

C2 - 33675862

SN - 0190-9622

VL - 85

SP - e173-e174

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

ER -

Bosma AL, de Wijs LEM, Hof MH, van Nieuwenhuizen BR, Gerbens LAA , Middelkamp-Hup MA et al. Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”. Journal of the American Academy of Dermatology. 2021 Sept;85(3):e173-e174. Epub 2021. doi: https://doi.org/10.1016/j.jaad.2021.02.072

Response to: “Comment on ‘Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry’”

Access to Document

Other files and links

Cite this